Advances in Psoriasis

Dr. Weinberg, is an Associate Clinical Professor of Dermatology at Mount Sinai School of Medicine, New York. In addition, he is director of the Clinical Research Center/Dermatopharmacology at St. Luke’s-Roosevelt Hospital Center and acting director of the Division of Dermatology at Jamaica Hospital Medical Center, both in New York City. Prior to this he was an Assistant Clinical Professor of Dermatology at Columbia University College of Physicians and Surgeons in New York City. Dr. Weinberg graduated from the University of Pennsylvania School of Medicine in Philadelphia and completed an internship in medicine at Columbia-Presbyterian Medical Center in New York City. He then completed a residency in dermatology at the University of Pennsylvania School of Medicine. He is a fellow of the American Academy of Dermatology, where he has served on several committees, and a member of the Dermatology Foundation. He is a diplomat of the American Board of Dermatology. Dr. Lebwohl graduated from Columbia University in 1974. He earned his medical degree from Harvard Medical School in 1978 and subsequently completed residencies in both internal medicine and dermatology at the Icahn School of Medicine at Mount Sinai. In 1983, he was made Assistant Professor of Dermatology at Mount Sinai. In 1997, he was named Chairman of the Department which, under his leadership, has been at the forefront of the management of psoriasis. He was the first to report the cardiac complications of pseudoxanthoma elasticum, and, additionally, he has developed new techniques for diagnosing the disease. He was also the first to use immunomodulators (imiquimod) to treat preccancerous skin lesions, the first to use topical calcineurin inhibitors to treat psoriasis, and the first to identify interactions between topical vitamin D analogues such as calcipotriol and calcitriol with other topical medications and with ultraviolet light. He has been at the forefront of clinical trials for new biologic therapies for psoriasis.

• Introduction to and History of Psoriasis and Psoriasis Therapy.- Pathophysiology of Psoriasis/Novel Pathways.- Psoriasis: Clinical Review and Update.- Psoriasis: Epidemiology, Potential Triggers, Disease Course.- Topical Therapy I: Corticosteroids and Vitamin D Analogues.- Topical Therapy II: Retinoids, Immunomodulators, and Others.- Topical Therapy II: Retinoids, Immunomuodulators, and Others/ Ultraviolet Therapy for Psoriasis.- Laser Therapy for Psoriasis.- Traditional Systemic Therapy I: Methotrexate and Cyclosporine.- Traditional Systemic Therapy II: Retinoids and Others.- Apremilast.- Etanercept.- Adalimumab.- Infliximab, Golimumab , and Certolizumab Pegol.- Ustekinumab.- Guselkumab.- Tidrakizumab.- Risankizumab.- Secukinumab.- Ixekizumab.- Brodalumab.- Biosimilars for Psoriasis.- Research Pipeline I: Oral Therapeutics for Psoriasis.- Research Pipeline II: Upcoming Biologic Therapies.- Pediatric Psoriasis.- Challenges in Psoriasis Treatment:  Nail, Scalp, and Palmoplantar Involvement.- Psoriasis and Comorbidities.- Summary of Published Treatment Guidelines.- Index.

Select Guide Rating